Xuchen Cao
Overview
Explore the profile of Xuchen Cao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
553
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao H, Zhou X, Wang G, Yu Y, Li Y, Chen Z, et al.
J Cancer
. 2024 Oct;
15(18):6002-6015.
PMID: 39440065
Triple-negative breast cancer (TNBC) is a poor prognostic subtype of breast cancer due to limited treatment. Macrophage plays a critical role in tumor growth and survival. Our study intends to...
2.
Feng R, Huang W, Min J, Shu W, Zhang Y, Yu Y, et al.
J Eval Clin Pract
. 2024 Oct;
PMID: 39396385
Purpose: By analyzing the existing data of this study, a prediction tool for the overall breast cancer survival and disease-free survival (DFS) of elderly women was established. Patients And Methods:...
3.
Huo G, Song Y, Liu W, Cao X, Chen P
Front Pharmacol
. 2024 Apr;
15:1300183.
PMID: 38606181
In the double-blind phase III ADAURA randomized clinical trial, adjuvant osimertinib showed a substantial overall survival benefit in patients with stage IB to IIIA, EGFR-mutated, completely resected non-small cell lung...
4.
Chen Y, Zhang T, Zhang R, Cao X
Cancer Biother Radiopharm
. 2024 Mar;
39(6):435-440.
PMID: 38527247
Pyrotinib, a new irreversible dual pan-human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase inhibitor blocking EGFR and HER2, has achieved a promising efficacy for advanced HER2-positive (HER2) breast...
5.
Zhao H, Li D, Li Q, Zhang B, Xiao C, Zhao Y, et al.
Oncologist
. 2024 Mar;
29(6):e763-e770.
PMID: 38459836
Background: To assess the efficacy and safety of tucidinostat plus exemestane as a neoadjuvant strategy in early-stage breast cancer. Methods: This prospective, open-label, single-arm phase II trial enrolled patients with...
6.
Feng R, Huang W, Liu B, Li D, Zhao J, Yu Y, et al.
Technol Health Care
. 2024 Feb;
32(4):2445-2461.
PMID: 38306071
Background: The effective treatment of breast cancer in elderly patients remains a major challenge. Objective: To construct a nomogram affecting the overall survival of triple-negative breast cancer (TNBC) and establish...
7.
PICALM as a Novel Prognostic Biomarker and Its Correlation with Immune Infiltration in Breast Cancer
A N, Lyu P, Yu Y, Liu M, Cheng S, Chen M, et al.
Appl Biochem Biotechnol
. 2024 Jan;
196(9):6011-6027.
PMID: 38175412
PICALM (phosphatidylinositol-binding clathrin assembly protein) mutations have been linked to a number of human disorders, including leukemia, Alzheimer's disease, and Parkinson's disease. Nevertheless, the effect of PICALM on cancer, particularly...
8.
Hai L, Feng Y, Zhao J, Tang Q, Wang X, Cao X, et al.
Cancer Control
. 2023 Sep;
29:10732748221122703.
PMID: 37735939
Background: The NCCN clinical guidelines recommended core needle biopsy for breast lesions classified as Breast Imaging Reporting and Data System (BI-RADS) 4, while category 4A lesions are only 2-10% likely...
9.
Wu J, Fan D, Shao Z, Xu B, Ren G, Jiang Z, et al.
Holist Integr Oncol
. 2023 Jul;
1(1):7.
PMID: 37520336
Purpose: Breast cancer is now the most common malignant tumor worldwide. About one-fourth of female cancer patients all over the world suffer from breast cancer. And about one in six...
10.
Feng R, Huang W, Chen L, Min J, Shu W, Yu Y, et al.
World J Surg Oncol
. 2023 Apr;
21(1):127.
PMID: 37032326
Introduction: Primary breast lymphoma (PBL) is a rare disease, treatment of which excerpts does not reach a consensus. This retrospective study was conducted to analyze clinical features and survival outcomes...